January 23, 2020
Weil advised Sanofi in its acquisition of all of the outstanding shares of Synthorx for $2.5 billion. Synthorx is a clinical-stage biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. The transaction closed on January 23, 2020.
The Weil team that advised Sanofi was led by Mergers & Acquisitions partner Michael J. Aiello and included Mergers & Acquisitions partner Amanda Fenster , Mergers & Acquisitions associates Stephen Liebscher, Samuel Son and Karl de la Roche (Not Yet Admitted in New York). The team also included Head of Technology & IP Transactions Michael Epstein; Tax partner Devon Bodoh; Head of Executive Compensation & Benefits Paul Wessel; Antitrust/Competition partner John Scribner; Co-Head of Patent Litigation and Life Sciences Elizabeth Weiswasser; International Arbitration & Trade partner Ted Posner; Cybersecurity, Data Privacy & Information Management Co-Head Randi Singer; Technology & IP Transactions associates Kane Wishart, Rami Sherman and Caleb Small (Not Yet Admitted in New York); Tax associates Steven Ort and Jesse Hong; Executive Compensation & Benefits associate Daniel Rios; and Patent Litigation associates Natalie Kennedy, Andrew Gesior and Saif Askar (Not Yet Admitted in New York).